Zeria Pharmaceutical Co., Ltd.
Tokyo Stock ExchangeTotal Valuation
Zeria Pharmaceutical Co., Ltd. carries a market capitalization of 91.46B, placing it among publicly traded companies globally. Its enterprise value stands at 118.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 91.46B |
| Enterprise Value | 118.52B |
Share Statistics
Zeria Pharmaceutical Co., Ltd. currently has 44.08M shares outstanding.
| Shares Outstanding | 44.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Zeria Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 42.86. The price-to-sales ratio is 2.56, and the price-to-book ratio stands at 1.41.
| PE Ratio | 42.86 |
| PS Ratio | 2.56 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 2.26 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Zeria Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 27.60 and an EV/FCF ratio of 692.25. The EV/Sales ratio of 3.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.60 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.04 |
| EV / EBITDA | 27.60 |
| EV / EBIT | 27.60 |
| EV / FCF | 692.25 |
Financial Position
Zeria Pharmaceutical Co., Ltd. maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 48.00, indicating elevated leverage, while an interest coverage ratio of 18.53 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.20 |
| Quick Ratio | 0.45 |
| Debt / Equity | 48.00 |
| Debt / EBITDA | 9.90 |
| Interest Coverage | 18.53 |
Financial Efficiency
Zeria Pharmaceutical Co., Ltd. posts a return on equity of 3.45 and a return on invested capital of 2.42.
| Return on Equity (ROE) | 3.45 |
| Return on Assets (ROA) | 1.52 |
| Return on Invested Capital (ROIC) | 2.42 |
| Return on Capital Employed (ROCE) | 2.23 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.72 |
Taxes
Over the trailing twelve months, Zeria Pharmaceutical Co., Ltd. has paid 808.12M in income taxes, reflecting an effective tax rate of 26.11.
| Income Tax | 808.12M |
| Effective Tax Rate | 26.11 |
Stock Price Statistics
Zeria Pharmaceutical Co., Ltd.'s stock has gained approximately 1.81551% over the past 52 weeks. The 50-day moving average sits at 2,173.20, while the 200-day moving average is 2,116.21.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1.81551% |
| 50-Day Moving Average | 2,173.20 |
| 200-Day Moving Average | 2,116.21 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zeria Pharmaceutical Co., Ltd. generated 39.05B in revenue and converted that into 2.33B in net income, yielding earnings per share of 51.89. EBITDA reached 4.29B, while operating income came in at 4.29B.
| Revenue | 39.05B |
| Gross Profit | 28.45B |
| Operating Income | 4.29B |
| Pretax Income | 3.10B |
| Net Income | 2.33B |
| EBITDA | 4.29B |
| EBIT | 4.29B |
| Earnings Per Share (EPS) | 51.89 |
Balance Sheet
Zeria Pharmaceutical Co., Ltd. holds 24.36B in cash and equivalents against 42.52B in total debt, resulting in a net debt position of 18.16B. Total book value stands at 70.94B, with working capital of 10.59B providing operational flexibility.
| Cash & Cash Equivalents | 24.36B |
| Total Debt | 42.52B |
| Net Debt | 18.16B |
| Equity (Book Value) | 70.94B |
| Book Value Per Share | 1,609.34 |
| Working Capital | 10.59B |
Margins
Zeria Pharmaceutical Co., Ltd. operates with a gross margin of 72.87, reflecting its pricing power and cost economics. The operating margin of 11.00 and net profit margin of 5.98 provide insight into operational efficiency.
| Gross Margin | 72.87 |
| Operating Margin | 11.00 |
| Pretax Margin | 7.93 |
| Profit Margin | 5.98 |
| EBITDA Margin | 11.00 |
Stock Splits
Zeria Pharmaceutical Co., Ltd.'s most recent stock split took place on September 26, 2013 with a 10:11 split ratio.
| Last Split Date | 9/26/2013 |
| Split Ratio | 10:11 |
Scores
Zeria Pharmaceutical Co., Ltd. posts an Altman Z-Score of 2.23, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.23 |